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ABSTRACT
MicroRNAs have been shown to play important roles in breast cancer progression 
and can serve as biomarkers. To assess the prognostic role of a panel of miRNAs 
in breast cancer, we collected plasma prospectively at the time of initial diagnosis 
from 1,780 patients with stage I-III breast cancer prior to definitive treatment. We 
identified plasma from 115 patients who subsequently developed distant metastases 
and 115 patients without metastatic disease. Both groups were matched by: age 
at blood collection, year of blood collection, breast cancer subtype, and stage. The 
median follow up was 3.4 years (range, 1-9 years). We extracted RNA from plasma 
and analyzed the expression of 800 miRNAs using Nanostring technology. We then 
assessed the expression of miRNAs in primary and metastatic breast cancer samples 
from The Cancer Genome Atlas (TCGA). We found that, miR-24-3p was upregulated in 
patients with metastases, both in plasma and in breast cancer tissues. Patients whose 
primary tumors expressed high levels of miR-24-3p had a significantly lower survival 
rate compared to patients with low mir-24-3p levels in the TCGA cohort (n=1,024). 
RNA-Seq data of the samples with the highest miR-24-3p expression versus those 
with the lowest miR-24-3p in the TCGA cohort identified a specific gene expression 
signature for those tumors with high miR-24-3p. Possible target genes for miR-24-
3p were predicted based on gene expression and binding site, and their effects on 
cancer pathways were evaluated. Cancer, breast cancer and proteoglycans were the 
top three pathways affected by miR-24-3p overexpression.
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INTRODUCTION
Breast cancer is the most common malignancy in 
women, accounting for 30% of new invasive cancers 
expected to be diagnosed in the US in 2017 [1]. The most 
important prognostic factor is the stage at presentation, 
which is determined by the tumor size, the number of 
axillary lymph nodes involved and the presence/absence 
of overt metastases. Although the presence of distant 
metastases at diagnosis (stage IV) is the most ominous 
sign, women with stage I-III may also harbor occult 
metastases. It takes years from the initial transformation 
events of mammary cells to the detection of imaging/
clinical changes that result in a breast cancer diagnosis. 
During this time cancer cells can spread through the 
circulation to distant sites. The metastatic process is 
extremely complex and requires adaption mechanisms 
by cancer cells including but not limited to migration, 
invasion, penetration into blood vessels, circulation 
through the bloodstream, extravasation and expansion 
in distant organs [2]. However, the regulation of the 
metastatic process at cellular and molecular levels is not 
well defined for individual patients. Molecular markers 
that are commonly used in clinical practice include the 
estrogen receptor (ER), progesterone receptor (PR), the 
human epidermal growth factor receptor 2 (HER2), the 
Ki-67 proliferation marker and multi-gene assays [3-
5]. These prognostic and predictive factors are used to 
estimate the risk of recurrence and the potential benefit 
associated with systemic therapies, including HER2-
targeted therapy, endocrine therapy and chemotherapy [6-
8]. Despite improvements in local, regional and systemic 
therapies for breast cancer, 40,610 women are expected to 
die from metastatic breast cancer in the US in 2017 [1]. 
Therefore, there is a need to identify novel prognostic 
and predictive markers of occult metastases to better 
individualize adjuvant systemic therapy and develop new 
therapeutic approaches to eradicate occult metastases in 
women with early-stage breast cancer [9, 10].
MicroRNAs (miRNAs) are small, noncoding RNA 
molecules 20-23 nucleotides in length that play key roles 
in regulation of cell division, differentiation, and death 
[11]. One of the main functions of miRNAs is to silence 
gene expression by binding to complementary sequences 
in the 3’UTR of target mRNAs [12]. Dysregulation of 
miRNA expression has been linked to carcinogenesis, 
invasion and metastasis [13]. MicroRNAs can be detected 
and quantified reliably in plasma and tissue from cancer 
patients and have potential as biomarkers [14, 15]. 
Previous studies revealed correlations between miRNA 
detection and prognosis in breast cancer. However, results 
have not been consistent or reproducible across studies in 
part because of the different populations evaluated and the 
methods used to identify miRNAs. Furthermore, there are 
limited data regarding molecular mechanisms for single 
miRNAs or miRNA signatures that may impact prognosis 
in breast cancer patients.
We conducted a study to determine the prognostic 
role of circulating plasma miRNAs in patients with early-
stage breast cancer. We measured the expression of 800 
miRNAs in plasma we collected prospectively at the time 
of diagnosis, before definitive primary treatment. We 
detected miRNAs that were expressed at higher levels 
in patients with stage I-III who subsequently developed 
metastatic disease. We then evaluated the differential 
expression of miRNAs in primary breast cancer tissue 
using The Cancer Genome Atlas (TCGA) database. Both 
analyses revealed mir-24-3p as a top candidate for further 
evaluation as a biomarker for breast cancer metastasis.
RESULTS
Plasma microRNA transcriptome analysis 
identifies 29 differentially expressed microRNA 
in patients with early-stage breast cancer who 
subsequently developed metastasis
Using Nanostring technology we profiled the 
microRNA transcriptome in plasma from 115 cases and 
115 controls, respectively. In total, we obtained expression 
levels of ~800 microRNAs. To identify potentially 
prognostic microRNAs, we performed differential 
expression analysis between the two patient groups 
using DEseq2. We identified 29 differentially expressed 
microRNAs in patients who developed metastasis 
compared to patients who did not: 24 microRNAs were 
upregulated while 5 were downregulated (Figure 1A). 
A comprehensive list of the significantly differentially 
expressed microRNAs is shown in Table 1.
mir-24-3p overexpression correlates with 
advanced stage, and triple negative/basal 
subtype in primary breast cancer tissues
Motivated by the discovery of differentially expressed 
microRNAs in the plasma of metastatic versus non-
metastatic patients, we then hypothesized that some of 
the microRNA transcripts we detected in the plasma may 
have originated in the primary tumors either via circulating 
tumor cell parts, microvesicles or via exosomes. To find 
supporting evidence for our hypothesis, we analyzed 
microRNA expression data obtained from TCGA. We 
then performed differential microRNA expression analysis 
between stage I and stage IV patients. As demonstrated in 
the volcano plot in Figure 1B, eleven microRNAs (out of 
a total of 1881 microRNAs) were significantly upregulated 
in primary tumors of stage IV versus stage I patients. 
Interestingly, mir-24-3p was also found to be upregulated in 
the plasma samples from metastatic versus non-metastatic 
patients in our cohort. Kaplan-Meier survival analysis 
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shows significantly lower survival rates (p-value=0.0024, 
quantile-based log-rank test) in patients with elevated levels 
of mir-24-3p in primary tumors from TCGA (Figure 1C).
For TCGA data, Multivariate Analysis of Variance 
(MANOVA) indicated the association of mir-24-3p 
expression with known prognostic factors, i.e. subtype, stage 
and survival time (p-value= 3.749e-12). Univariate Analysis 
of Variance (ANOVA and t-test) has been performed on 
tumor subtypes and the results indicate showing a significant 
(p-value < 0.001) difference between different subtypes 
(Figure 1D). We also examined the association of mir-24-3p 
survival with subtype and stage found a positive association 
in univariate analysis (p = 0.009) that remained statistically 
significant after adjusting for intrinsic subtype and stage 
(p = 0.004) (Supplementary Figure 1, right panel (B)). A 
similar trend was observed in the Nanostring plasma dataset 
(Supplementary Figure 1, left panel (A)), however it was 
marginally significant, probably due to the limited number of 
patients and lower levels of mir-24-3p in plasma compared to 
tumor tissue. In our patient cohort, there was no difference in 
mean mir-24-3p between grade I and grade II tumors, but the 
mean mir-24-3p expression in grade III tumors was higher 
than in grade I tumors (p=0.04). Grade was not available for 
TCGA (Supplementary Figure 1).
Figure 1: (A) Volcano plot of differentially expressed miRNAs in metastatic and non-metastatic serum samples obtained by Nanostring 
data analysis. Upregulated miRNAs are plotted in red and downregulated in blue (B) Volcano plot of differentially expressed miRNAs in 
TCGA stage I versus stage IV primary tumor samples. Upregulated miRNAs in Stage IV are plotted in red and downregulated in blue (C) 
Survival curve of mir-24-3p in TCGA patients (D). Distribution of mir-24-3p across different tumor subtypes in TCGA primary tumors.
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mir-24-3p is associated with pathways 
upregulated in cancer
Because of the significant correlation of mir-
24-3p expression levels with patient survival rates, 
we further investigated its potential regulatory role in 
primary tumors. We sorted the TCGA samples based on 
their mir-24-3p expression and took the top 25 and the 
bottom 25 samples to perform differential expression 
analysis on those conditions or two patients groups 
(Figure 2A). Dimensionality reduction of protein-coding 
gene expression profiles of the two patient groups using 
t-distributed stochastic neighbor embedding [16] revealed 
a good separation of the two patient groups (Figure 2B), 
suggesting that tumors with high mir-24-3p expression 
are dependent on transcriptional programs that are distinct 
from the ones active in patients with low mir-24-3p 
expression. To identify these transcriptional programs, 
we first performed differential expression analysis of the 
protein-coding genes (TCGA RNA-Seq data) between the 
Table 1: List of the significantly differentially expressed microRNAs in plasma of metastatic vs. non-metastatic 
patients
Gene_name Control_mean Metastasis_mean foldChange pvalue padj
hsa-miR-126-3p 421.9134289 676.8186276 1.604164697 0.002945286 0.069244359
hsa-miR-130a-3p 82.35289258 126.8828971 1.540721803 0.003637321 0.069244359
hsa-miR-181a-5p 26.338105 40.11759065 1.523176806 0.001810582 0.069244359
hsa-miR-106a-5p+hsa-miR-17-5p 42.32371603 61.78223478 1.459754496 0.004196628 0.069244359
hsa-miR-15a-5p 57.75558022 84.09167839 1.455992271 0.010034894 0.091986529
hsa-miR-142-3p 307.0759047 447.0948109 1.455974904 0.015969554 0.098567251
hsa-let-7g-5p 85.84623264 124.5787981 1.451185384 0.012432581 0.097684567
hsa-miR-146a-5p 25.87165231 37.48361606 1.448829615 0.000658213 0.067224967
hsa-miR-15b-5p 113.2087794 162.6198738 1.436459917 0.016786562 0.098567251
hsa-miR-199a-5p 34.088818 48.15377871 1.412597489 0.006576129 0.083466246
hsa-miR-191-5p 114.5181748 161.0017431 1.405905598 0.017323941 0.098567251
hsa-miR-27b-3p 17.42951055 24.09008977 1.38214379 0.011079524 0.096216921
hsa-miR-20a-5p+hsa-miR-20b-5p 45.18030217 60.63153392 1.341990447 0.014262422 0.098567251
hsa-let-7d-5p 22.86627562 30.65721483 1.340717454 0.012421539 0.097684567
hsa-miR-24-3p 16.88318331 22.53860549 1.334973689 0.009161539 0.091986529
hsa-miR-19b-3p 27.72094601 36.77714893 1.326691698 0.014876929 0.098567251
hsa-miR-106b-5p 16.56919141 21.93428224 1.323799194 0.006447937 0.083466246
hsa-miR-98-5p 14.76934433 19.54707704 1.323489831 0.009004442 0.091986529
hsa-let-7i-5p 49.96965086 65.92391001 1.31927898 0.008677135 0.091986529
hsa-miR-185-5p 19.81740991 26.10801207 1.317428069 0.002642304 0.069244359
hsa-miR-151a-3p 18.06574804 23.53997512 1.303016906 0.016270605 0.098567251
hsa-miR-92a-3p 18.98911204 24.51292998 1.290893957 0.003233125 0.069244359
hsa-miR-361-5p 14.98231138 19.2511097 1.284922547 0.016185416 0.098567251
hsa-miR-32-5p 21.20346146 26.94874863 1.27095987 0.009784947 0.091986529
hsa-miR-516a-3p+hsa-miR-516b-3p 17.43257585 16.02094928 -1.088111294 0.013722192 0.098567251
hsa-miR-518f-3p 20.49794068 18.74217241 -1.093680083 0.002215359 0.069244359
hsa-miR-125b-5p 19.52071838 17.705905 -1.102497635 0.00400355 0.069244359
hsa-miR-1293 16.4858169 14.89180043 -1.107039876 0.005290175 0.07935262
hsa-miR-1236-3p 17.64853298 15.68462151 -1.125212552 0.000814848 0.067224967
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two patient groups. This analysis yielded a large number 
of differentially expressed genes (2128 upregulated and 
1190 downregulated), highlighted in the volcano plot 
in Figure 2C. The top 500 significantly differentially 
expressed genes are depicted using an expression 
heatmap representation in Figure 2D. Pathway analysis 
of these protein-coding genes identified several pathways 
involved in cancer. Top three pathways includes pathways 
in cancer (KEGG: has05200), proteoglycans in cancer 
(KEGG: 05205) and breast cancer (KEGG: hsa05224) 
(Figure 3A). A detailed overview of all the significantly 
(FDR < 0.1) differentially expressed genes in pathways in 
cancer (KEGG: has05200 are shown in Figure 3B. Similar 
pathway overviews were obtained for breast cancer 
(Supplementary Figure 2) and proteoglycans in cancer 
(Supplementary Figure 3).
mir-24-3p protein-coding target genes are 
involved in cancer pathways
We identified 746 putative protein coding target 
genes for mir-24-3p using TargetScan (http://www.
targetscan.org). We then examined whether mir-24-3p 
putative targets are significantly differentially expressed in 
TCGA samples with high mir-24-3p compared to samples 
with low mir-24-3p expression. Of the 745 genes, 316 
Figure 2: (A) Box-plot of mir-24-3p levels in patients showing the highest (n=25) and lowest (n=25) expressing levels of mir-24-3p in 
primary tumors from the TCGA (B) t-SNE plot of patients with high and low mir-24-3p expressing levels showing the separation of the two 
conditions (C) Volcano plot of the genes differentially expressed based on mir-24-3p expression in primary tumors (high versus low) (D) 
Heatmap of the top 500 genes differentially expressed in patients with high versus low mir-24-3p levels.
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genes were significantly differentially expressed (FDR < 
0.1). Of these, 134 genes were down-regulated and 182 
genes were up-regulated when mir-24-3p levels were high 
(Figure 4A). To identify the most stringent list of putative 
targets, we additionally filtered the 316 genes based on 
fold change and identified 27 genes significantly down-
regulated by more than 2-fold in patients with high levels 
of mir-24-3p (Figure 4B). A pathway analysis of all the 
target genes revealed that mir-24-3p may significantly 
regulate genes involved in cancer (p-value < 0.05) 
(Supplementary Figure 4).
DISCUSSION
Using nanostring and RNA-sequencing 
technologies we identified miR-24-3p as a potential 
Table 2: Patient characteristics
Cases
n = 115
Controls
n = 115
Age at diagnosis, years
 Median (range) 48 (22, 83) 48 (24, 88)
Race/ethnicity
 Caucasian 66 (57%) 69 (60%)
 African-American 25 (22%) 16 (14%)
 Asian/Pacific Islanders 5 (4%) 6 (5%)
 Hispanic 18 (16%) 23 (20%)
 Other 1 (1%) 1 (1%)
Menopausal status at diagnosis
 Premenopausal 54 (47%) 58 (51%)
 Perimenopausal 4 (3%) 9 (8%)
 Postmenopausal 57 (50%) 48 (41%)
Stage at sample collection
 I 4 (3%) 4 (3%)
 II 49 (43%) 55 (48%)
 III 62 (54%) 56 (49%)
Subtype based on ER, PR, HER2
 ER/PR+ and HER2- 57 (50%) 58 (50%)
 HER2+ 19 (16%) 18 (16%)
 Triple negative 39 (34%) 39 (34%)
Year of sampling
 2003 12 (10%) 8 (7%)
 2004 14 (12%) 22 (19%)
 2005 23 (20%) 17 (15%)
 2006 16 (14%) 14 (12%)
 2007 12 (10%) 17 (15%)
 2008 27 (23%) 27 (23%)
 2009 11 (10%) 10 (9%)
Time to metastases, years
 Median (range) 2.3 (0.6, 9.0) -
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novel marker of breast cancer metastases in breast 
cancer. MiR-24-3p was expressed at high levels in the 
plasma from early-stage breast cancer patients destined 
to metastasize despite best available therapy, and in 
primary breast cancer tissue from patients who presented 
with stage IV at the time of diagnosis. High expression 
of mir-24-3p in primary breast cancer tissues correlated 
with a poor survival rate in TCGA. These data strongly 
suggest mir-24-3p is involved in the metastatic process 
in breast cancer patients.
Figure 4: Circos plots depicting (A) 316 deferentially expressed genes (FDR < 0.1) out of 745 target genes detected by TargetScan for 
mir-24-3p (differentially expressed in patients with high mir-24-3p levels vs. low miR-24). Red arcs show genes upregulated and blue 
downregulated in samples with high mir-24-3p and the histogram represents the fold change. (B) 27 significantly down regulated genes 
(FDR < 0.1 & fold change > 2) out of 745 target genes detected by TargetScan for mir-24-3p showing the most possible targets.
Figure 3: (A) The top three significantly (P value < 0.05) effected pathways in patients with high mir-24-3p vs. low mir-24-3p (n=50) 
(B) Heat map overview of the principal pathways involved in cancer (KEGG: hsa05200). Upregulated genes are in red and downregulated 
genes are shown in green.
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There is great interest in the development of liquid 
biopsies using next generation sequencing. While most 
studies are focussed on the detection of mutations at the 
DNA level, Nanostring and RNA-Seq technologies allow 
detection of nucleic acids in plasma and tissues with 
high sensitivity and specificity. The demonstration that 
miRNAs are stable and can be extracted from tissues, 
blood, and other body fluid without degradation makes 
them ideal biomarkers for diagnosis and prognosis in 
breast cancer and other solid tumors. A meta-analysis 
of studies designed to determine the prognostic role of 
plasma miRNAs in patients with triple negative breast 
cancer showed a correlation between high circulating 
miRNA expression and lower disease-free survival, 
relapse-free survival and distant metastasis-free survival 
rates [17]. Sochor and collaborators [18] found that 
high-risk patients (classified as TNBC, HER2, highly 
proliferative or with positive node involvement) expressed 
higher levels in plasma of miRNAs related to cancer 
(oncomiRs), including miR-2. Several studies have 
identified mir-24-3p as a potential oncomiR in breast 
cancer, as its expression is specifically upregulated in both 
tumor and plasma from patients that developed the disease 
compare to healthy controls [19].
RNA-Seq data reported by Fiskaa, et al [20] and 
Hannafon, et al [21] showed mir-24-3p is released from the 
cells in exosomes. We re-analyzed the data in both studies 
and found that mir-24-3p is significantly upregulated in 
breast cancer cell lines versus non-breast cancer cell lines 
(p-value<0.05 using a t-test). (data not shown).
In addition to the strong correlation between plasma 
levels of mir-24-3p and the probability of developing 
metastasis in patients with early-stage of breast cancer, 
we identified a specific gene expression signature in 
patients with high levels of mir-24-3p in primary tumors. 
Interestingly, differential gene expression analysis showed 
that the principal genes deregulated are affecting the main 
pathways related to cancer, such as survival, migration and 
proliferation, pathways directly related to the process of 
metastasis.
Many studies have linked the expression of mir-
24-3p with breast cancer progression and metastasis 
by regulating genes and signaling pathways associated 
with cell cycle progression [19], DNA repair and drug 
resistance [22]. mir-24-3p directly targets p27(Kip1) 
and p16(Ink4a) in primary keratinocyte and in different 
cancer derived cell lines promoting their proliferation, 
suggesting that mir-24-3p is involved in carcinogenesis 
by post-transcriptional regulation of cyclin-dependent 
kinase [23]. Du et al. observed that mir-24-3p was 
upregulated in breast cancer tissues compared to benign 
tissues in a small cohort of patients. In vitro and in 
vivo studies indicated that the expression of mir-24-
3p enhanced tumor growth, invasion into local tissues, 
metastasis to lung tissues and decreased overall mouse 
survival by direct targeting PTPN0 and PTPRF and 
therefore downregulating phosphorylation levels of 
EGFR [24]. In another study, the authors reported that 
mir-24-3p expression was significantly increased in HCC 
metastatic tumor tissues compared with matched non-
metastatic tumor tissues. These authors showed that mir-
24-3p could down-regulate p53 through binding to the 
3’-UTR of p53 mRNA, resulting in enhanced invasion 
in HCC cell lines [25]. Additionally, a recent report 
provides compelling data in support for a direct role of 
mir-24-3p in promoting breast tumor cell growth and 
metastasis in a xenograft mouse model via the regulation 
of ING5 [26]. Altogether, our results suggest that the 
overexpression of mir-24-3p during early-stages of breast 
cancer could drive gene-expression reprogramming to a 
more metastatic phenotype in breast cancer, and that the 
levels in plasma of mir-24-3p could be used as a feasible 
biomarker for patient prognosis and therefore help 
decision-making for treatment options.
In summary, we have identified mir-24-3p as 
a potential plasma biomarker of occult metastasis in 
patients with stage I-III breast cancer. Furthermore, we 
found that mir-24-3p is highly expressed in metastatic 
breast cancer tissue compared to primary breast cancer 
tissue, and that those tumors show specific gene 
expression signature. Our data show mir-24-3p plays an 
important role in regulation of the metastatic process in 
breast cancer, and justifies prospective studies to confirm 
the role of mir-24-3p and its gene targets as novel 
prognostic and predictive markers.
MATERIALS AND METHODS
Study subjects
A whole blood sample was collected prospectively 
at The University of Texas MD Anderson Cancer Center 
from 1,780 patients with stage I-III breast cancer, from 
6/18/03 to 2/20/2012 after obtaining Institutional Review 
Board approval and written informed consent from 
participants. The blood sample was collected after initial 
diagnosis and prior to definitive treatment, which included 
either primary surgery or neoadjuvant chemotherapy 
depending on the clinical stage. All patients were treated 
uniformly with standard local and systemic therapies. 
Blood samples were centrifuged at x1200 g for 10 minutes 
at 4°C to separate the blood cells, and the supernatant 
was transferred into microcentrifuge tubes and then 
centrifuged a second time at x12,000 g for 10 minutes 
at 4°C to completely remove the cellular components. 
Plasma was aliquoted and stored at −80°C until use. Blood 
samples were processed and plasma was frozen within 4 
hours of collection. Only patients recruited from 2003 to 
2009 were used in the present study to ensure sufficient 
follow-up. At a median follow up of 3.4 years (range, 1-9 
years), 119 patients developed distant metastases. Each of 
these patients was matched to a patient who was alive and 
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not diagnosed with metastases at follow-up time equal or 
greater to that at which the case was diagnosed with her 
first metastasis (control). The matching factors were age 
(+/- 5 years) at blood collection, year of blood collection, 
breast cancer subtype, and stage. Out of total 119 cases, 
4 cases were excluded because no eligible controls were 
found. As a result, 115 cases and 115 matched controls 
are included in the analysis. A summary of the patient 
characteristics is shown in Table 2.
RNA extraction
Total RNA was extracted from plasma using the 
Plasma/Serum RNA Purification Midi Kit (Norgen Biotek 
Corp.) according to the manufacturer’s instructions. Spike 
in oligos were added as an internal control following the 
final lysis step according to the manufacturer’s instructions. 
Eluted RNA volume was brought up to 420μl using nuclease 
free water and passed through a pre-wet Amicon Ultra-0.5 
Centrifugal Filter Device (EMD Millipore). Diluted RNA 
was spun for 80 minutes at 14,000xg at room temperature 
and then for 2 minutes at 8,000xg to collect concentrated 
RNA, at a final volume of 20-25μl.
Nanostring for assessment of microRNA 
expression
RNA quality and quantity were analyzed on an 
agilent Bioanalyzer 2100 using a pico chip. miRNA 
samples were hybridized using the Nanostring nCounter 
® Human v3 miRNA Expression Assay, which includes 
800 microRNAs, according to the manufacturer’s 
protocol. 3uL of concentrated miRNA were used per 
sample. Hybridizations were processed on the nCounter 
Prep Station, and prepped cartridges were read on the 
Nanostring Digital Analyzer using 280 field of view 
counts. Data was analyzed with Nanostring nSolver 2.0. 
All samples were analyzed together using the default 
quality control measures and normalized to spike-ins 
added to samples before extraction.
Computational analysis
Raw nanostring data is preprocessed using 
Nanostring nSolver 2.0. First, the background threshold is 
determined, either in probe specific or more global manner. 
Then, the background is subtracted to determine the true 
counts. This subtraction generally improves downstream 
data analysis, such as fold-change estimation. The 
background subtracted nanostring data is then corrected 
for library sizes and differential expression analysis is 
performed using DESeq2. The read count tables for all 
the BRCA miRNA illumine sequencing samples (1207 
samples) in TCGA were downloaded from The National 
Cancer Institute’s (NCI) Genomic Data Commons (GDC). 
Of these samples, primary solid tumor samples (N=1047, 
with complete clinical data annotation for cancer stage) 
and normal tissue samples (N=104) were used in this 
study. All the read count tables were then corrected for 
their library size differences based on their geometric 
library size factors using the DESeq2 package (v3.0) [27]; 
differential expression (DE) analysis was performed using 
this package. The PCA plots were visualized using ggplot2 
package and the R ‘dist’ function was used to calculate 
the sample distances by setting the method as Euclidean. 
Euclidian distance heat-maps were visualized using 
ggplot2’s “heatmap.2” function. mir-24-3p expression 
were used for survival analysis using Kaplan-Meier curves 
(n=1024). Log-rank test was used to test for the survival 
distributions amongst our sample groups. The mean of 
miR24 expression was used as a threshold for low and 
high limits and the survival objects were calculated using 
the rms R package. Pathway analysis was performed using 
the clusterprofiler package [28]. We used TargetScan for 
miRNA target prediction. The Circo plots were generated 
using CIRCOS [29].
Statistical analysis
For both data sets, wald test p values and adjusted 
p values provided by DESeq2 package were used 
for differential expression analysis (adjusted p < 0.1) 
which is based on estimating dispersions and uses a 
negative binomial generalized linear model. For sample 
clustering, we performed a classical multidimensional 
scaling or Principal Component Analysis (PCA), 
t-distributed stochastic neighbor embedding (t-SNE) and 
a Euclidean distance based clustering. We used ANOVA 
and MANOVA to examine the association of mir-24-3p 
with known prognostic factors, i.e. subtype, grade, stage 
and survival time. For pathway and enrichment analysis, 
we used hypergeometric distribution tests performed by 
clusterProfiler package (adjusted p < 0.1). The data in both 
data sets were individually and comprehensively analyzed 
and visualized all in the R statistical environment (v3.2.5). 
The Cox proportional hazards model was used to assess 
the association of subtype, stage, and mir-24-3p with 
survival in the TCGA dataset. The log-rank test was also 
used for testing the survival rates and distributions.
Statement of significance
We identified mir-24-3p as a novel marker of occult 
metastases in plasma from patients with stage I-III breast 
cancer using nanostring technology. RNA-Seq data from 
The Cancer Genome Atlas showed association of mir-24-
3p expression and metastases in primary breast cancer 
tissue. Expression of mir-24-3p was associated with poor 
survival, suggesting a potential role as a novel prognostic 
marker in breast cancer. Furthermore, molecular pathways 
regulated by mir-24-3p are potential therapeutic targets for 
metastatic breast cancer.
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Data accession
All the raw count tables for nanostring data and it’s 
quality control tests areprovided in the supplementary data 
(Supplementary data 2 and 3). Theclinical metadata for 
the nanostring samples are provided in supplementary data 
1. TCGA mir-24-3p expression profiles and their clinical 
information areprovided in supplementary data 4.
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